

reasonable likelihood that such radiation doses may have endangered the health of members of this class. SPR was established to aid the Advisory Board in carrying out its duty to advise the Secretary, HHS, on dose reconstruction. SPR is responsible for overseeing, tracking, and participating in the reviews of all procedures used in the dose reconstruction process by the NIOSH Division of Compensation Analysis and Support (DCAS) and its dose reconstruction contractor (Oak Ridge Associated Universities—ORAU).

Matters for Discussion: The agenda for the Subcommittee meeting includes: Discussion of procedures in the following ORAU and DCAS technical documents:

OCAS Technical Information Bulletin (TIB) 0014 (“Rocky Flats Internal Dosimetry Coworker Extension”), ORAU OTIB 0013 (“Individual Dose Adjustment Procedures for Y–12 Dose Reconstructions”), ORAU OTIB 0029 (“Internal Dose Reconstructions for Y–12”), ORAU OTIB 0039 (“Internal Dose Reconstructions for Hanford”), ORAU OTIB 0050 (“The Use of Rocky Flats Neutron Dose Reconstruction Project Data in Dose Reconstructions”), ORAU OTIB 0060 (“Internal Dose Reconstructions”), Program Evaluation Report (PER) 003 (“The Effects of Adding Ingestion Intakes to Bethlehem Steel Cases”), PER 004 (“Application of Photofluorography at the Pinellas Plant”), PER 005 (“Misinterpreted Application of External Dose Factor for Hanford Dose Reconstructions”), PER 029 (“Hanford TBD Revision”), PER 042 (“Linde Ceramic Plant TBD Revision”), PER 045 (“Aliquippa Forge TBD Revision”), ORAU PROC 0042 (“Incomplete Monitoring at Y–12”), ORAU RPRT 0044 (“Analysis of Bioassay Data with Significant Fraction of Less-Than Results”); and a continuation of the comment-resolution process for other dose reconstruction procedures under review by the Subcommittee. The agenda is subject to change as priorities dictate.

Contact Person For More Information: Theodore Katz, Designated Federal Officer, NIOSH, CDC, 1600 Clifton Road, Mailstop E–20, Atlanta, Georgia 30329–4027, Telephone (513) 533–6800, Toll Free 1(800) CDC–INFO, Email ocas@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2016–09268 Filed 4–20–16; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

The meeting announced below concerns the CDC National Centers for Excellence in Youth Violence Prevention: Operations Research (Implementation Science) for Strengthening Program Implementation through the President’s Emergency Plan for AIDS Relief (PEPFAR), RFA–GH–16–005, initial review.

SUMMARY: This publication corrects a notice that was published in the **Federal Register** on March 22, 2016 Volume 81, Number 55, pages 15307. The meeting place should read as follows:

DATES: *Times and Dates:*

9:00 a.m.–2:00 p.m., EDT, Panel A, April 26, 2016 (Closed)

9:00 a.m.–2:00 p.m., EDT, Panel B, April 27, 2016 (Closed)

FOR FURTHER INFORMATION CONTACT:

Hylan Shoob, Scientific Review Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 1600 Clifton Road NE., Mailstop D–69, Atlanta, Georgia 30033, Telephone: (404) 639–4796, HMS4@CDC.GOV.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2016–09269 Filed 4–20–16; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day–16–1061]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570 or send an email to omb@cdc.gov. Written comments and/or suggestions regarding the items contained in this notice should be directed to the Attention: CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written comments should be received within 30 days of this notice.

Proposed Project

Behavioral Risk Factor Surveillance System (BRFSS) (OMB Control No. 0920–1061, exp. 3/31/2018)—Revision—National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP)—Centers for Disease Control and Prevention (CDC).

Background and Brief Description

CDC is requesting OMB approval to revise information collection for the Behavioral Risk Factor Surveillance System (BRFSS). The BRFSS is a nationwide system of annual, cross-sectional telephone health surveys sponsored by CDC. BRFSS coordinators in health departments in U.S. states, territories, and the District of Columbia (collectively referred to as states) collaborate with CDC on questionnaire content and survey administration.

An independent sample of adult, non-institutionalized respondents is drawn each for each state and is based on the state's parameters for state-level or sub-state analysis. Each state's annual questionnaire is based on a common core that is administered by all states. In addition, CDC provides support for standardized optional modules that states can use to collect customized content. Information collection is conducted in a continuous, three-part telephone interview process: Screening, participation in core BRFSS questions,

and participation in the optional question modules. Both the core survey and the optional modules are updated annually.

CDC requests OMB approval to incorporate a limited annual field test into the BRFSS clearance. Field testing will be conducted approximately 5–8 months in advance of the principal BRFSS survey. Field tests are used to identify problems with new or updated questions, instrument documentation or instructions, software errors, or other implementation issues. Field tests are typically conducted in one state. Addition of the annual field test will increase the estimated annualized number of responses by 900 and the estimated annualized burden by 382 hours. These estimates include allocations for both respondent screening and completion of the field test survey. Each year CDC will use the Change Request mechanism to request OMB approval of the annual Field Test Supplement.

CDC and the states will continue to use BRFSS data to produce state-level

information about adults 18 years and older. BRFSS topics include health risk behaviors, health conditions, and preventive health practices that are associated with chronic diseases, infectious diseases, and injury. This information is used by state and local health departments to plan and evaluate public health programs at the state or sub-state level. In addition, CDC makes annual BRFSS data sets available for public use and provides guidance on statistically appropriate uses of the data.

Field test results will not be incorporated into the analytic data sets. Field test results are used exclusively to inform the development of the upcoming year's BRFSS questionnaire and the technical assistance that CDC provides to states.

OMB approval is requested for three years. Participation in the BRFSS is voluntary and there are no costs to respondents other than their time. The total estimated annualized burden hours are 256,297.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents	Form name	Number of respondents	Number of responses per respondent	Average burden per response (in hr)
U.S. General Population	Landline Screener	440,486	1	1/60
	Cell Phone Screener	223,334	1	1/60
Adults ≥18 Years	Field Test Screener	400	1	1/60
	Core Survey	494,650	1	15/60
	Optional Modules	484,757	1	15/60
	Field Test Survey	500	1	45/60

Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2016–09189 Filed 4–20–16; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2016–N–0832]

Phibro Animal Health Corp.; Carbadox in Medicated Swine Feed; Opportunity for Hearing; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of opportunity for hearing; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a

notice that appeared in the **Federal Register** on April 12, 2016 (81 FR 21559). The document announced an opportunity for a hearing on FDA's Center for Veterinary Medicine's proposal to withdraw approval of all new animal drug applications providing for use of carbadox in medicated swine feed and contained an incorrect telephone number for the individual to be contacted for further information. The address for Phibro Animal Health Corp. was also incorrect. This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Vernon Toelle, Center for Veterinary Medicine (HFV–234), 7519 Standish Pl., Rockville, MD 20855, 240–402–7001.

SUPPLEMENTARY INFORMATION: In FR Doc. 2016–08327, appearing on page 21559 in the **Federal Register** of Tuesday, April 12, 2016, the following corrections are made:

1. On page 21560, in the second column, in the **FOR FURTHER**

INFORMATION CONTACT paragraph, the telephone number is corrected to read “240–402–7001”.

2. On page 21560, in the third column, in the first paragraph, the address for Phibro Animal Health Corp. is corrected to read “GlenPointe Centre East, 3d floor, 300 Frank W. Burr Blvd., suite 21, Teaneck, NJ 07666”.

3. On page 21572, in the first column, in the third paragraph, the address for Phibro Animal Health Corp. is corrected to read “GlenPointe Centre East, 3d floor, 300 Frank W. Burr Blvd., suite 21, Teaneck, NJ 07666”.

Dated: April 18, 2016.

Tracey Forfa,
Acting Director, Center for Veterinary Medicine.

[FR Doc. 2016–09265 Filed 4–20–16; 8:45 am]

BILLING CODE 4164–01–P